ダウンロード数: 505
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
62_7_341.pdf | 732.74 kB | Adobe PDF | 見る/開く |
タイトル: | 過活動膀胱を有する前立腺肥大症患者に対する薬物治療の臨床的検討 : クロスオーバー法を用いた比較検討 |
その他のタイトル: | A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin |
著者: | 宇都宮, 紀明 松本, 敬優 常森, 寛行 六車, 光英 川喜田, 睦司 上山, 裕樹 金丸, 聰淳 伊藤, 哲之 塚崎, 秀樹 白波瀬, 敏明 高橋, 毅 |
著者名の別形: | Utsunomiya, Noriaki Matsumoto, Keiyu Tsunemori, Hiroyuki Muguruma, Koei Kawakita, Mutsushi Kamiyama, Yuki Kanamaru, Sojun Ito, Noriyuki Tsukazaki, Hideki Shirahase, Toshiaki Takahashi, Takeshi 兵庫UB(Unstable Bladder)研究会 Hyogo UB (Unstable Bladder) Study Group |
キーワード: | OAB BPH Naftopidil |
発行日: | 31-Jul-2016 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 62 |
号: | 7 |
開始ページ: | 341 |
終了ページ: | 347 |
抄録: | We compared the efficacy of naftopidil monotherapy with combination therapy using tamsulosin hydrochloride and solifenacin succinate in the treatment of lower urinary tract symptoms (LUTS) with overactive bladder (OAB) secondary to benign prostatic hyperplasia (BPH). Thirty one patients were enrolled in a randomized crossover study. Fourteen patients were initially prescribed naftopidil 75 mg (N) for 8 weeks, followed by tamsulosin 0.2 mg and solifenacin 5 mg (TS) for 8 weeks (group N) ; another 17 were initially prescribed TS, followed by N (group TS). The efficacy variables were the changes in international prostate symptom score (I-PSS), quality of life (QOL) score, overative bladder symptom score (OABSS), and post-void residual (PVR) urine volume. After the study, a questionnaire survey was carried out about the choice of treatment. After treatment with each agent, total I-PSS, storage symptom score, QOL score and OABSS except for the daytime frequency were significantly improved from baseline. PVR was significantly increased after TS treatment. There were no significant differences between the two treatments except for PVR. As a result of the questionnaire survey, 13 patients chose N and 17 chose TS. In conclusion, N monotherapy can be expected to have an equal effect in the treatment of LUTS with OAB secondary to BPH in comparison with TS combination therapy. |
著作権等: | 許諾条件により本文は2017/08/01に公開 |
DOI: | 10.14989/ActaUrolJap_62_7_341 |
URI: | http://hdl.handle.net/2433/216315 |
PubMed ID: | 27569351 |
出現コレクション: | Vol.62 No.7 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。